<DOC>
	<DOCNO>NCT02346240</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety two dose level certolizumab pegol compare active comparator placebo adult moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>Efficacy Safety Study Certolizumab Pegol ( CZP ) Versus Active Comparator Placebo Subjects With Plaque Psoriasis ( PSO )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Provided informed consent Adult men woman ≥ 18 year Chronic plaque psoriasis least 6 month Baseline psoriasis activity severity index ≥ 12 body surface area ≥ 10 % Physician 's Global Assessments score ≥ 3 Candidate systemic psoriasis therapy and/or phototherapy and/or chemophototherapy Other protocoldefined inclusion criterion may apply Erythrodermic , guttate , generalize pustular form psoriasis History current , chronic , recurrent infection viral , bacterial , fungal origin describe protocol Congestive heart failure History lymphoproliferative disorder include lymphoma current sign symptom suggestive lymphoproliferative disease History malignancy concurrent malignancy describe protocol History , suspect , demyelinate disease central nervous system ( e.g. , multiple sclerosis optic neuritis ) Female subject breastfeeding , pregnant , plan become pregnant study within 3 month follow last dose study drug . Male subject plan partner pregnancy study within 10 week follow last dose Any condition , Investigator 's judgment , would make subject unsuitable participation study Other protocoldefined exclusion criterion may apply Prior Etanercept use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Psoriasis</keyword>
</DOC>